

In the specification:

Please amend the paragraph beginning at page 1, line 7 as follows:

This application is a continuation of 08/466,465, filed June 6, 1995, now U.S. Patent No. 6,162,432, which is a continuation-in-part of USSN 07/862,022, filed April 2, 1992, now abandoned, and of PCT/US92/08755, filed October 6, 1992, which is a continuation-in-part of USSN 07/770,969, filed October 7, 1991, now abandoned, all of which are herein incorporated by reference.

Please amend the paragraph beginning at page 12, line 19, as follows:

Soluble LFA-3 polypeptides may be derived from the transmembrane form of LFA-3, particularly the extracellular domain (e.g., AA<sub>1</sub>-AA<sub>187</sub> of SEQ ID NO:2). Such polypeptides are described in U.S. Patent No. 4,956,281 and co-pending U.S. Patent Application Serial No. 07/667,971 (which shares a common assignee with the present application), which are herein incorporated by reference. Preferred soluble LFA-3 polypeptides include polypeptides consisting of AA<sub>1</sub>-AA<sub>92</sub> of SEQ ID NO:2, AA<sub>1</sub>-AA<sub>80</sub> of SEQ ID NO:2, AA<sub>50</sub>-AA<sub>65</sub> of SEQ ID NO:2 and AA<sub>20</sub>-AA<sub>80</sub> of SEQ ID NO:2. A vector comprising a DNA sequence encoding SEQ ID NO:2 (i.e., SEQ ID NO:1) is deposited with the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209 Rockville, Maryland under Accession No. 75107.

Please amend the paragraph beginning at page 12, line 28, as follows:

The most preferred fusion proteins of this type contain the amino terminal 92 amino acids of mature LFA-3, the C-terminal 10 amino acids of a human IgG1 hinge region containing the two cysteine residues thought to participate in interchain disulfide bonding, and the C<sub>H</sub>2 and C<sub>H</sub>3 regions of a human IgG1 heavy chain constant domain (e.g., SEQ ID NO:8). This fusion protein is referred to herein as "LFA3TIP." A plasmid, pSAB152, encoding an exemplary LFA3TIP is deposited with American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209 Rockville, Maryland under the accession number ATCC 68720. The DNA sequence of the pSAB152 insert is SEQ ID NO:7.

Please amend the paragraph beginning at page 13, line 14, as follows:

Soluble LFA-3 polypeptides may also be derived from the PI-linked form of LFA-3, such as those described in PCT Patent Application Serial No. WO 90/02181. A vector comprising a DNA sequence encoding PI-linked LFA-3 (i.e., SEQ ID NO:3) is deposited with the American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209 ~~Rockville, Maryland~~ under Accession No. 68788. It is to be understood that the PI-linked form of LFA-3 and the transmembrane form of LFA-3 have identical amino acid sequences through the entire extracellular domain. Accordingly, the preferred PI-linked LFA-3 polypeptides are the same as for the transmembrane form of LFA-3.

Please amend the paragraph beginning at page 12, line 36, as follows:

One way of producing LFA3TIP for use in the methods of this invention is described in co-pending, commonly assigned U.S. Patent Application Serial No. 07/770,967. Generally, conditioned culture medium of COS7 or CHO cells transfected with pSAB152 was concentrated using an AMICON® S1Y30 spiral cartridge system (AMICON®, Danvers, Massachusetts) and subjected to Protein A-Sepharose® 4B (Sigma, St. Louis, Missouri) chromatography. The bound proteins were eluted and subjected to Superose®-12 (Pharmacia/LKB, Piscataway, New Jersey) gel filtration chromatography.

Please amend the paragraph beginning at page 20, line 34, as follows:

Peripheral blood mononuclear cells ("MNC") were isolated from heparinized blood using Ficoll-Hypaque® (Pharmacia) density gradient centrifugation according to manufacturer's suggested protocol. Resting CD4<sup>+</sup> T cells were prepared as follows. Macrophages were removed by plastic adherence at 37°C for 1 hour. The nonadherent, macrophage-depleted MNC were washed, and then depleted of CD8<sup>+</sup> T lymphocytes, activated T cells, B cells, antigen presenting cells and NK cells by incubation with monoclonal antibodies to CD8 (ATCC CRL 8014), HLA-DR (ATCC CRL H355), and CD11b (ATCC CRL 8026). These antibodies were used as dilutions in PBS (1:200) of ascites fluid from pristane-primed mice.

Please amend the paragraph beginning at page 26, line 30, as follows:

Murine hybridoma cells and anti-LFA-3 antibodies useful in the present invention are exemplified by cultures deposited under the Budapest Treaty with American Type Culture Collection, 10801 University Boulevard, Manassas, VA 20110-2209 ~~Rockville, Maryland~~ U.S.A., on March 5, 1991, and identified as: